

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)



(10) International Publication Number
WO 2022/175750 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/00 (2006.01)
A61K 51/10 (2006.01) C07K 16/18 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2022/000077

(22) International Filing Date:

18 February 2022 (18.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/152,079 22 February 2021 (22.02.2021) US

(71) Applicant: **ABDERA THERAPEUTICS INC.** [CA/CA];
2405 Wesbrook Mall, Vancouver, British Columbia V6T
1Z3 (CA).

(72) Inventors: **JUDGE, Adam**; 2405 Wesbrook Mall, Van-
couver, British Columbia V6T 1Z3 (CA). **ABRAMS,**
Michael; 2405 Wesbrook Mall, Vancouver, British Colum-
bia V6T 1Z3 (CA). **MANDEL, Alexander Laurence**; 2405
Wesbrook Mall, Vancouver, British Columbia V6T 1Z3
(CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY




FIG. 1A




FIG. 1B

(57) Abstract: Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 and 110 kDa. The immunoconjugates can be used to deliver alpha and beta emitters for the treatment of tumors or cancer.